{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:34:01Z","timestamp":1785443641088,"version":"3.56.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41440-026-02572-1","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:49:17Z","timestamp":1772077757000},"page":"1778-1781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduction of interstitial fluid retention by combination therapy with dapagliflozin, an SGLT2 inhibitor, and conventional diuretics: comment on a post-hoc analysis of the DAPA-BODY trial"],"prefix":"10.1038","volume":"49","author":[{"given":"Takuya","family":"Tomaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2572_CR1","doi-asserted-by":"publisher","unstructured":"Masuda T, Asakura-Kinoshita M, Oka K, Ohara K, Sakai M, Miura M, et al. SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial. Hypertens Res 2025. https:\/\/doi.org\/10.1038\/s41440-025-02388-5..","DOI":"10.1038\/s41440-025-02388-5"},{"key":"2572_CR2","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.3390\/jcm13216502","volume":"13","author":"E La Porta","year":"2024","unstructured":"La Porta E, Faragli A, Herrmann A, Lo Muzio FP, Estienne L, Geniere Nigra S, et al. Bioimpedance analysis in CKD and HF patients: a critical review of benefits, limitations, and future directions. J Clin Med. 2024;13:6502.","journal-title":"J Clin Med"},{"key":"2572_CR3","first-page":"576","volume":"79","author":"JE Novak","year":"2022","unstructured":"Novak JE. Diuretics in states of volume overload: core curriculum. Am J Kidney Dis. 2022;79:576\u201390.","journal-title":"Am J Kidney Dis"},{"key":"2572_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10157-017-1397-6","volume":"21","author":"YH Khan","year":"2017","unstructured":"Khan YH, Sarriff A, Adnan AS, Khan AH, Mallhi TH. Outcomes of diuretic use in pre-dialysis CKD patients with moderate renal deterioration attending tertiary care referral center. Clin Exp Nephrol. 2017;21:723\u201330.","journal-title":"Clin Exp Nephrol"},{"key":"2572_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752\u201372.","journal-title":"Circulation"},{"key":"2572_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215\u201325.","journal-title":"Diabetologia"},{"key":"2572_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1287066","volume":"10","author":"K Oka","year":"2023","unstructured":"Oka K, Masuda T, Ohara K, Miura M, Morinari M, Misawa K, et al. Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY trial. Front Med (Lausanne). 2023;10:1287066.","journal-title":"Front Med (Lausanne)"},{"key":"2572_CR8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coemr.2019.07.005","volume":"9","author":"M Christ-Crain","year":"2019","unstructured":"Christ-Crain M. Vasopressin and copeptin in health and disease. Curr Opin Endocr Metab Res. 2019;9:56\u201364.","journal-title":"Curr Opin Endocr Metab Res"},{"key":"2572_CR9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/diagnostics14111194","volume":"14","author":"M Asakura-Kinoshita","year":"2024","unstructured":"Asakura-Kinoshita M, Masuda T, Oka K, Ohara K, Miura M, Morinari M, et al. Sodium-glucose cotransporter 2 inhibitor combined with conventional diuretics ameliorate body fluid retention without excessive plasma volume reduction. Diagnostics (Basel). 2024;14:1194.","journal-title":"Diagnostics (Basel)"},{"key":"2572_CR10","doi-asserted-by":"publisher","first-page":"F361","DOI":"10.1152\/ajprenal.00070.2022","volume":"323","author":"T Masuda","year":"2022","unstructured":"Masuda T, Ohara K, Vallon V, Nagata D. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats. Am J Physiol Ren Physiol. 2022;323:F361\u2013F369.","journal-title":"Am J Physiol Ren Physiol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02572-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:04:41Z","timestamp":1778105081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02572-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2572"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02572-1","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}